Spots Global Cancer Trial Database for Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Official Title: Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Study ID: NCT01113970
Conditions
Interventions
Study Description
Brief Summary: This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast cancer and may have received any number of prior therapies for their disease. It is expected that the Phase I portion will enroll up to 20 patients and the Phase II portion will enroll up to 45 patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
The West Clinic, Memphis, Tennessee, United States
Evergreen Hematology Oncology, Spokane, Washington, United States
Northwest Cancer Specialists, Vancouver, Washington, United States
Contact Details
Name: Jonathan J. Lewis, MD, PhD
Affiliation: ZIOPHARM, Oncology, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
